Published in Contraception on October 08, 2010
Contraceptive method and pregnancy incidence among women in HIV-1-serodiscordant partnerships. AIDS (2012) 1.24
High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2014) 0.97
Pregnancy and contraceptive use among women participating in an HIV prevention trial in Tanzania. Sex Transm Infect (2012) 0.94
Pregnancy incidence and correlates during the HVTN 503 Phambili HIV vaccine trial conducted among South African women. PLoS One (2012) 0.86
Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial. PLoS One (2013) 0.81
Pregnancy incidence and risk factors among women participating in vaginal microbicide trials for HIV prevention: systematic review and meta-analysis. PLoS One (2013) 0.80
Pregnancy incidence and correlates in a clinical trial preparedness study, North West Province South Africa. PLoS One (2014) 0.75
Ethical issues for late-stage trials of multipurpose prevention technologies for HIV and pregnancy. Int J Gynaecol Obstet (2014) 0.75
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (2012) 4.26
Microbicide drug candidates to prevent HIV infection. Lancet (2007) 3.06
Performance of a rapid and simple HIV testing algorithm in a multicenter phase III microbicide clinical trial. Clin Vaccine Immunol (2011) 1.47
FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. J Acquir Immune Defic Syndr (2014) 1.36
Expanded Phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS (2005) 1.23
Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr (2003) 1.23
Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? J Acquir Immune Defic Syndr (2013) 1.20
The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J Acquir Immune Defic Syndr (2015) 1.10
Intravaginal and intrarectal microbicides to prevent HIV infection. CMAJ (2005) 1.10
Baseline factors associated with incident HIV and STI in four microbicide trials. Sex Transm Dis (2010) 1.09
Obtaining valid laboratory data in clinical trials conducted in resource diverse settings: lessons learned from a microbicide phase III clinical trial. PLoS One (2010) 1.05
HIV prevention in women: next steps. Science (2011) 1.04
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. AIDS Behav (2015) 1.03
What predicts non-retention in microbicide trials? Contemp Clin Trials (2011) 1.03
Changes in sexual behavior during a safety and feasibility trial of a microbicide/diaphragm combination: an integrated qualitative and quantitative analysis. AIDS Educ Prev (2007) 0.99
The safety of candidate vaginal microbicides since nonoxynol-9: a systematic review of published studies. AIDS (2009) 0.95
Correlation of prospective and cross-sectional measures of HIV type 1 incidence in a higher-risk cohort in Ho Chi Minh City, Vietnam. AIDS Res Hum Retroviruses (2011) 0.94
Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. J Acquir Immune Defic Syndr (2014) 0.94
Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial. J Acquir Immune Defic Syndr (2016) 0.87
HIV prevention research: the ecstasy and the agony. Lancet (2008) 0.87
Vaginal microbicides can interfere with nucleic acid amplification tests used for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae infection. Diagn Microbiol Infect Dis (2006) 0.87
Behavioural and medical predictors of bacterial vaginosis recurrence among female sex workers: longitudinal analysis from a randomized controlled trial. BMC Infect Dis (2013) 0.86
Intermediate vaginal flora is associated with HIV prevalence as strongly as bacterial vaginosis in a cross-sectional study of participants screened for a randomised controlled trial. Sex Transm Infect (2012) 0.85
Pregnancy and contraceptive use among women participating in the FEM-PrEP trial. J Acquir Immune Defic Syndr (2015) 0.82
Structural accelerated failure time models for the effects of observed exposures on repeated events in a clinical trial. Stat Med (2005) 0.82
A dose-ranging phase I study of dextrin sulphate, a vaginal microbicide, in HIV-negative and HIV-positive female volunteers. Sex Transm Dis (2005) 0.82
The evolving design and methods for trials evaluating the safety of candidate vaginal microbicides: a systematic review. Sex Transm Dis (2013) 0.82
Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men. Sex Transm Dis (2007) 0.80
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. BMC Pharmacol Toxicol (2014) 0.79
Results of a safety and feasibility study of the diaphragm used with ACIDFORM Gel or K-Y Jelly. Contraception (2009) 0.79
Overcoming recruitment challenges: lessons learned from a safety and feasibility study of a diaphragm/microbicide combination in South Africa. J Acquir Immune Defic Syndr (2007) 0.79
Antiretroviral preexposure prophylaxis for HIV prevention. N Engl J Med (2013) 0.77
Intermediate vaginal flora and bacterial vaginosis are associated with the same factors: findings from an exploratory analysis among female sex workers in Africa and India. Sex Transm Infect (2013) 0.77
Response to Morrison et al., "Hormonal contraception and the risk of HIV acquisition". AIDS (2007) 0.75
Notes on the frequency of routinely collected and self-reported behavioral data in HIV prevention trials. AIDS Behav (2011) 0.75